Join Growin Stock Community!

Eyepoint pharmaceuticals, inc.EYPT.US Overview

US StockHealthcare
(No presentation for EYPT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EYPT AI Insights

EYPT Overall Performance

EYPT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EYPT Recent Performance

2.82%

Eyepoint pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

EYPT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EYPT Key Information

EYPT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EYPT Profile

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Price of EYPT

EYPT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EYPT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
34.34
PB Ratio
7.39
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
94.08%
Net Margin
-485.95%
Revenue Growth (YoY)
-7.38%
Profit Growth (YoY)
-4.75%
3-Year Revenue Growth
-54.13%
3-Year Profit Growth
-69.47%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
34.34
PB Ratio
7.39
Price-to-FCF
-
Gross Margin
94.08%
Net Margin
-485.95%
Revenue Growth (YoY)
-7.38%
Profit Growth (YoY)
-4.75%
3-Year Revenue Growth
-54.13%
3-Year Profit Growth
-69.47%

  • When is EYPT's latest earnings report released?

    The most recent financial report for Eyepoint pharmaceuticals, inc. (EYPT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EYPT's short-term business performance and financial health. For the latest updates on EYPT's earnings releases, visit this page regularly.

  • What is the operating profit of EYPT?

    According to the latest financial report, Eyepoint pharmaceuticals, inc. (EYPT) reported an Operating Profit of -62.03M with an Operating Margin of -6,420.81% this period, representing a decline of 89.4% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is EYPT's revenue growth?

    In the latest financial report, Eyepoint pharmaceuticals, inc. (EYPT) announced revenue of 966K, with a Year-Over-Year growth rate of -90.82%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does EYPT have?

    At the end of the period, Eyepoint pharmaceuticals, inc. (EYPT) held Total Cash and Cash Equivalents of 74.73M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does EYPT go with three margins increasing?

    In the latest report, Eyepoint pharmaceuticals, inc. (EYPT) did not achieve the “three margins increasing” benchmark, with a gross margin of 25.4%%, operating margin of -6,420.81%%, and net margin of -6,183.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EYPT's profit trajectory and future growth potential.

  • Is EYPT's EPS continuing to grow?

    According to the past four quarterly reports, Eyepoint pharmaceuticals, inc. (EYPT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.85. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EYPT?

    Eyepoint pharmaceuticals, inc. (EYPT)'s Free Cash Flow (FCF) for the period is -60.15M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 48.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.